Filtered By:
Therapy: Statin Therapy
Countries: China Health

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 86 results found since Jan 2013.

Impact of Low-density Lipoprotein Cholesterol Levels on Outcomes in Nonvalvular Atrial Fibrillation: Results from the China Atrial Fibrillation Registry Study
CONCLUSIONS In patients with NVAF using standard or no lipid-lowering medication, low plasma LDL-C levels were related to an increased risk of stroke/thromboembolism and cardiovascular mortality.PMID:35418552 | DOI:10.12659/MSM.934747
Source: Medical Science Monitor - April 14, 2022 Category: Research Authors: Zhi-Zhao Li Xin Du Nian Liu Xue-Yuan Guo Chao Jiang Liu He Shi-Jun Xia Wei Wang Ri-Bo Tang San-Shuai Chang Rong-Hui Yu De-Yong Long Rong Bai Cai-Hua Sang Song-Nan Li Jian-Zeng Dong Chang-Sheng Ma Source Type: research

Need for hyperlipidemia management policy reform in China: learning from the global experience.
CONCLUSIONS: New hyperlipidemia prevention policies must set a time-bound target, need to be a patient and clinician centric in terms of its applications, and revised periodically for long-term benefits. PMID: 28696793 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - July 12, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

Continued Statin Prescriptions After Adverse Reactions and Patient Outcomes: A Cohort Study.
Conclusion: Continued statin prescriptions after an adverse reaction were associated with a lower incidence of death and cardiovascular events. Primary Funding Source: Chinese National Key Program of Clinical Science, National Natural Science Foundation of China, and Young Scientific Research Fund of Peking Union Medical College Hospital. PMID: 28738423 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - July 25, 2017 Category: Internal Medicine Authors: Zhang H, Plutzky J, Shubina M, Turchin A Tags: Ann Intern Med Source Type: research

Early Statin in Stroke; ' Chinese Finger Trap ' Valve; Disasters Hurt Vasculature, Too
(MedPage Today) -- Recent developments of interest in cardiovascular medicine
Source: MedPage Today Primary Care - October 16, 2017 Category: Primary Care Source Type: news

Treatment of atherosclerosis by traditional Chinese medicine: Questions and quandaries
Atherosclerosis and its complications, such as myocardial infarction and stroke, are the major causes of morbidity and mortality, and development of effective therapeutics for both prevention and treatment of this disease is critically important. Currently, there are many drugs available for atherosclerotic disease, but the lipid-lowering drugs statins are still the first-choice for treatment of hypercholesterolemia, a major risk factor for atherosclerosis. On the other hand, traditional Chinese medicines, mainly Chinese herbal medicines (CHM), have been widely used in China and in other Asian countries for the treatment o...
Source: Atherosclerosis - August 30, 2018 Category: Cardiology Authors: Chuan Wang, Manabu Niimi, Teruo Watanabe, Yanli Wang, Jingyan Liang, Jianglin Fan Tags: Review article Source Type: research

Apelin-13 Suppresses Neuroinflammation Against Cognitive Deficit in a Streptozotocin-Induced Rat Model of Alzheimer ’s Disease Through Activation of BDNF-TrkB Signaling Pathway
Conclusion The data in this manuscript demonstrates that apelin-13 upregulates BDNF against STZ-induced congnitive impairment by suppressing glial cell activity and inflammatory factors release. This suggests apelin signaling may be a new target in the treatment of AD. Ethics Statement All experimental protocols were carried out according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals approved by the Central South University at XiangYa Animal Care and Use Committee. Author Contributions XqQ and LH conceived the study and contributed to its experimental design. HqL carried out the...
Source: Frontiers in Pharmacology - April 15, 2019 Category: Drugs & Pharmacology Source Type: research

Ability to Suppress TGF- β-Activated Myofibroblast Differentiation Distinguishes the Anti-pulmonary Fibrosis Efficacy of Two Danshen-Containing Chinese Herbal Medicine Prescriptions
Conclusion: This study suggests that a clinically efficacious cardiovascular Chinese herbal medicine (DLP) can be successfully repurposed to treat a lung disease in pulmonary fibrosis guided by TCM theory. Our comparative study between DLP and DHP demonstrated a critical requirement of suppressing both pro-inflammatory and pro-fibrotic pathways for the treatment of pulmonary fibrosis, supporting that a multi-component prescription capable of “removing both phlegm and blood stasis” will better achieve co-protection of heart and lung in PHD. Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic ...
Source: Frontiers in Pharmacology - April 23, 2019 Category: Drugs & Pharmacology Source Type: research

Contemporary Invasive Management and In-hospital Outcomes of Patients with Non-ST-segment Elevation Myocardial Infarction in China: Findings from China Acute Myocardial Infarction (CAMI) Registry
ConclusionInvasive management was underused and profoundly deferred among patients with NSTEMI in China. The risk-treatment paradox, procedure deferral and medical resources distribution imbalance may represent opportunities for improvement.
Source: American Heart Journal - June 6, 2019 Category: Cardiology Source Type: research

Contemporary invasive management and in-hospital outcomes of patients with non–ST-segment elevation myocardial infarction in China: Findings from China Acute Myocardial Infarction (CAMI) Registry
ConclusionInvasive management was underused and profoundly deferred among patients with NSTEMI in China. The risk-treatment paradox, procedure deferral and medical resources distribution imbalance may represent opportunities for improvement.
Source: American Heart Journal - June 29, 2019 Category: Cardiology Source Type: research

Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study
Publication date: Available online 30 August 2019Source: The Lancet Global HealthAuthor(s): John K Lin, Andrew E Moran, Kirsten Bibbins-Domingo, Bode Falase, Andrea Pedroza Tobias, Charuta N Mandke, Dhruv S KaziSummaryBackgroundFewer than 25% of patients with atherosclerotic cardiovascular disease in countries of low and middle income (LMICs) use guideline-directed drugs for secondary prevention. A fixed-dose combination polypill might improve cardiovascular outcomes by increasing prescription rates and adherence, but the cost-effectiveness of this approach is uncertain.MethodsWe developed microsimulation models to assess ...
Source: The Lancet Global Health - September 1, 2019 Category: International Medicine & Public Health Source Type: research

Impacts of Clinical Pharmacist Intervention on the Secondary Prevention of Coronary Heart Disease: A Randomized Controlled Clinical Study
This study aimed to investigate the impact of clinical pharmacist intervention on the prognosis of acute coronary syndrome (ACS) in Chinese patients with CHD. Two hundred and forty patients who had ACS were recruited. Participants were randomly assigned to the intervention group (n = 120) or the control group (n = 120). The intervention group received a medication assessment and education by the clinical pharmacist at discharge and telephone follow-ups at 1 week and 1 and 3 months after discharge. The control group received usual care. The primary outcomes of this study were the proportion of patients who had major adverse...
Source: Frontiers in Pharmacology - October 7, 2019 Category: Drugs & Pharmacology Source Type: research

How to continue lipid-lowering therapy in patients with coronary heart disease and severe liver dysfunction?: A case report of plaque regression by a combination of Chinese and Western Medicine
Rationale: Atherosclerotic cardiovascular disease (ASCVD), including coronary heart disease (CHD), atherosclerotic stroke and peripheral vascular disease, has become the most deadly chronic noncommunicable disease throughout the world in recent decades, while plaque regression could reduce the occurrence of ASCVD. Traditional Chinese Medicine (TCM) has been widely used for prevention and treatment of these diseases. In the perspective of TCM, phlegm and blood stasis are considered to be leading pathogenesis for CHD. Hence, activating blood circulation and dissipating phlegm, which is of great benefit to regress plaque, h...
Source: Medicine - October 1, 2019 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

Europe ’s doctors urge tighter curbs in Chinese medicine
Chinese medicines ‘must meet’ same standards of proof and evidence as conventional medicine Related items fromOnMedica Pharmacists could offer high-dose statins direct to patients Clinicians need better options if we are to stop over-medication Prescription drug dependence linked to deprivation Stroke survivors need more help taking medicine Statins of small and uncertain benefit in primary prevention
Source: OnMedica Latest News - November 6, 2019 Category: UK Health Source Type: news

Effects of High Dose of Atorvastatin for Preventing Periprocedural Ischemic Brain Damage in Patients Undergoing Carotid Artery Stenting (PICAS) in China: A Randomized Controlled Clinical Trial
This study is the first to assess whether high-dose atorvastatin treatment is capable of reducing the incidence of perioperative cerebral ischemic injury in patients of Chinese ethnicity undergoing CAS. These results will offer evidence regarding which statin treatment regimens are more appropriate when treating Chinese patients undergoing CAS in an effort to minimize their risk of any perioperative cerebral ischemic injury.Trial Registration:ClinicalTrials.gov NCT03079115; registered March 14, 2017.
Source: Frontiers in Neurology - August 24, 2020 Category: Neurology Source Type: research